admin – Page 2660 – Get News Story

Myelodysplastic Syndrome Pipeline Outlook Report 2025: Key 120+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insights 2025” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Myelodysplastic Syndrome Pipeline Outlook Report

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

In August 2025, Novartis Pharmaceuticals announced a study is designed to evaluate the efficacy and safety of eltrombopag monotherapy in Japanese adult patients with platelet transfusion-dependent lower-risk Myelodysplastic syndromes (LR-MDS).
In August 2025, H. Lee Moffitt Cancer Center and Research Institute conducted a study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA).
DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
The leading Myelodysplastic Syndrome Companies such as Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals and others.
Promising Myelodysplastic Syndrome Therapies such as Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.

Learn how leading Myelodysplastic Syndrome Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Myelodysplastic Syndrome Clinical Trials Assessment

Myelodysplastic Syndrome Emerging Drugs Profile

Tamibarotene: Syros Pharmaceuticals

Tamibarotene (formerly SY-1425) is an oral selective retinoic acid receptor alpha (RARα) agonist. The company is developing treatments for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene. Approximately 50% of MDS patients and 30% of AML patients have RARA overexpression. When RARα is expressed in excess of its tightly controlled natural ligand, cells in the bone marrow may not differentiate into healthy myeloid cells, which can lead to hematological malignancies. However, when oral tamibarotene is administered, tamibarotene binds to RARα, allowing for the restoration of gene expression and myeloid differentiation. The company is currently investigating tamibarotene in the Phase III SELECT-MDS-1 trial in newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA overexpression.

RVU120: Ryvu Therapeutics

RVU120 (SEL120) is a specific, selective inhibitor of CDK8 and its paralog, CDK19. Preclinical studies indicated the strong antileukemic potential of RVU120, which was often associated with the multilineage commitment of CD34+ AML cells. Moreover, RVU120 could improve proliferation and induce erythroid differentiation of CD34+ cells derived from Diamond-Blackfan anemia (DBA) patients. Currently, the drug is in the Phase II stage of its development for the treatment of Myelodysplastic syndromes.

Emavusertib: Curis

Emavusertib, which is being developed by Curis, is a small-molecule IRAK4 kinase inhibitor. Inhibition of IRAK4-L activity with emavusertib (CA-4948) blocks leukemic growth in non-clinical experiments. Because IRAK4 plays a central role in this pathway, it is considered an attractive target for the generation of therapeutics to treat these B-cell malignancies as well as certain inflammatory diseases. As part of the collaboration with Aurigene, in October 2015, Curis exclusively licensed a program of orally available, small molecule inhibitors of IRAK4 kinase, including emavusertib (CA-4948). Currently, the drug is in the Phase I/II stage of its development for the treatment of Myelodysplastic syndromes.

MNV-201: Minovia Therapeutics

MNV-201 is an investigational cell therapy developed by Minovia Therapeutics, targeting low-risk Myelodysplastic Syndromes (MDS). It utilizes a novel approach known as Mitochondrial Augmentation Technology (MAT), which involves enriching a patient’s own hematopoietic stem and progenitor cells (HSPCs) with mitochondria derived from allogeneic placental sources. This therapy aims to address mitochondrial dysfunction, which is implicated in the pathophysiology of MDS. Currently, MNV-201 is undergoing a Phase I clinical trial (NCT06465160) that is actively recruiting participants. The study’s primary objective is to evaluate the safety and therapeutic effects of MNV-201 in patients diagnosed with low-risk MDS.

The Myelodysplastic Syndrome Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Myelodysplastic Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelodysplastic Syndrome Treatment.
Myelodysplastic Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Myelodysplastic Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelodysplastic Syndrome market.

From early-stage research to late-phase Myelodysplastic Syndrome Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs- Download now! @ Myelodysplastic Syndrome Treatment Drugs

Myelodysplastic Syndrome Companies

Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Stay updated with the latest Myelodysplastic Syndrome Pipeline Insights! @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspectives

Scope of the Myelodysplastic Syndrome Pipeline Report

Coverage- Global
Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
Myelodysplastic Syndrome Therapies- Deferasirox, Bortezomib, Decitabine and cedazuridine, Luspatercept, Epoetin Alfa, and others.
Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Dive deep into rich insights for new drugs for Myelodysplastic Syndrome Treatment, visit @ Myelodysplastic Syndrome Drugs

Table of Content

Introduction
Executive Summary
Myelodysplastic Syndrome: Overview
Pipeline Therapeutics
Therapeutic Assessment
Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tamibarotene: Syros Pharmaceuticals
Mid Stage Products (Phase II)
CA-4948: Curis
Early Stage Products (Phase I)
MNV-201: Minovia Therapeutics
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Myelodysplastic Syndrome Key Companies
Myelodysplastic Syndrome Key Products
Myelodysplastic Syndrome- Unmet Needs
Myelodysplastic Syndrome- Market Drivers and Barriers
Myelodysplastic Syndrome- Future Perspectives and Conclusion
Myelodysplastic Syndrome Analyst Views
Myelodysplastic Syndrome Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelodysplastic Syndrome Pipeline Outlook Report 2025: Key 120+ Companies and Breakthrough Therapies Shaping the Future Landscape

Major Depressive Disorder Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Major Depressive Disorder Pipeline Insight 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight’s comprehensive report today! @ Major Depressive Disorder Pipeline Outlook

Key Takeaways from the Major Depressive Disorder Pipeline Report

In August 2025, Neumora Therapeutics Inc. announced a study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy and safety of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), and complete the 6 weeks double-blind treatment, provide informed consent, and meet eligibility criteria, may enter this extension study.
In August 2025, Cybin IRL Limited announced a study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.
In August 2025, Neurocrine Biosciences conducted a study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.

Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Medication

Major Depressive Disorder Emerging Drugs Profile

SAGE-217: Sage Therapeutics

SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD).

REL-1017: Relmada Therapeutics Inc.

REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.

Seltorexant: Minerva Sciences

Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

SP-624: Sirtsei Pharmaceuticals, Inc.

SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc.

SPL026: Small Pharma

SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world’s first DMT clinical trial for depression, in collaboration with Imperial College London.

PDC-1421: BioLite Inc.

PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development.

The Major Depressive Disorder Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Medication.
Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market

Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Medication. Access DelveInsight’s detailed report now! @ New Major Depressive Disorder Drugs

Major Depressive Disorder Companies

GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Subcutaneous
Intravenous
Intramuscular

Major Depressive Disorder Products have been categorized under various Molecule types such as

Bispecific Antibody
Peptides
Small molecule
Gene therapy

Unveil the future of Major Depressive Disorder Medication. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Major Depressive Disorder Market Drivers and Barriers

Scope of the Major Depressive Disorder Pipeline Report

Coverage- Global
Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others.
Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others.
Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Major Depressive Disorder Medication and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Major Depressive Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Major Depressive Disorder – DelveInsight’s Analytical Perspective
Late Stage Products (Preregistration)
SAGE-217: Sage Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
SP-624: Sirtsei Pharmaceuticals, Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SPL026: Small Pharma
Drug profiles in the detailed report…..
Preclinical Stage Products
Drug Name: Company name
Drug profiles in the detailed report…..
Inactive Products
Major Depressive Disorder Key Companies
Major Depressive Disorder Key Products
Major Depressive Disorder- Unmet Needs
Major Depressive Disorder- Market Drivers and Barriers
Major Depressive Disorder- Future Perspectives and Conclusion
Major Depressive Disorder Analyst Views
Major Depressive Disorder Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Major Depressive Disorder Pipeline Outlook Report 2025: Key 75+ Companies and Breakthrough Therapies Shaping the Future Landscape

Award-Winning European Agency Marketing King Powering Client Growth with Transparent, Flat-Rate Marketing

Bulgaria-based agency Marketing King was recently awarded the 2024 Media Innovator Award by Innovation in Business for Europe’s most innovative digital marketing service provider. Clients reported measurable marketing impact, sustained growth across channels, and outstanding customer service.

With over 1,500 projects completed, Marketing King has become Europe’s go-to versatile marketing agency. Innovation in Business recently chose Marketing King as a 2024 Media Innovator Awards recipient, naming the company the year’s most innovative digital marketing service provider in Europe.

“In an age where first impressions happen online, your website is more than a digital business card it’s a round-the-clock destination for prospects to discover who you are, what you do, and why you’re the best choice,” said Marketing King Founder and CEO Jonathan Bouckaert.

Marketing King helps clients’ businesses connect with their audience. The company has more than 10 years of experience in the industry, and the talented team uses that knowledge to craft creative marketing strategies that deliver results. Clients build lasting relationships with their audience through Marketing King’s carefully curated and targeted digital solutions. Whether a client needs marketing, branding, SEO and SEA, social media engagement and content creation, website design, webshops, or the whole package, Marketing King will develop a customized plan with seamless integration.

“Your path to business growth starts with our digital strategies, designed for your success,” Bouckaert said. “We transform your brand with cutting-edge strategies, ensuring it thrives in today’s competitive market.”

Marketing King delivers tailored solutions that drive engagement and growth, regardless of which area a client needs assistance with. From social media marketing to website design, the company crafts strategies to elevate any operation to new heights. Marketing King has an impressive 100% customer satisfaction across thousands of projects, with 90% customer retention.

Since signing on with Marketing King, clients have reliably experienced a 40% boost in organic traffic growth and have generated more than 10 million leads. The company has a proven track record of dramatic success with clients in industries like construction, wellness, pharmaceuticals, and tech.

“At Marketing King, we don’t just solve problems we solve them harder, smarter, and faster,” Bouckaert said. “Our approach to digital solutions is designed to elevate your brand and create meaningful connections with your audience.”

Marketing King delivers results that speak for themselves. Over 20 client websites launched in under 12 weeks, and SEO clients reported an average of 50–200% increased organic reach for three months. Many clients also experienced a significant return on investment from email, content, and social campaigns tailored to their company’s specific needs. Customer reviews praised the company’s fast response times, clear project communication, and high-quality deliverables.

One reviewer stated that Marketing King “transforms simple ideas into concrete and professional tools for business with all the necessary features included.” Another satisfied client wrote that the company provided a “quick and professional experience, with a personal touch.”

Discover how affordable it can be to have Marketing King transform a company’s growth and scalability with the “Build Your Own Package” pricing calculator. Choose services like SEO, branding, web design, ads, and more for one transparent, flat rate, regardless of company size.

“With our Build Your Package tool, you can assemble your ideal website or webshop in just a few clicks, fully tailored to your needs and goals,” Marketing King representatives said. “Select what matters to you, see what it costs, and get a complete proposal in your inbox.”

In an ever-changing and dynamic field, Marketing King believes every company deserves affordable, tailored solutions that address their specific needs without hidden fees. Marketing King’s proven process provides digital marketing strategies that drive measurable results and growth by increasing revenue and online visibility.

Discover the perfect site plan with Marketing King’s innovative quote builder, which starts with a five-step survey to learn the client’s needs and ends with instant, transparent pricing and a detailed proposal built around their goals.

Visit the official Marketing King website to learn more about the versatile collection of digital marketing services. Get started today with a personalized quote tailored to each client’s specific needs. Follow Marketing King on Facebook, Instagram, and X for social media content, important company updates, and relevant industry news.

Media Contact
Company Name: Marketing King
Email: Send Email
Country: Bulgaria
Website: https://marketingking.eu

US Army Multiple Orders for Video Compression with Large Scalable Potential, Plus Grant Initiative on Tele-Remote Video in Underground Uses: RMX Industries (Stock Symbol: RMXI)

$RMXI Proprietary Platform Delivers High-Impact Results in Ultra-Low-Bandwidth Environments, Enabling Real-Time Video Where Traditional Solutions Fail

• Video Technology Provider Focused on the Growing Global Demand for High Performance Video Data Transmission and Storage.

• Optimized for Defense to AI and Enterprise Applications.

• Military Applications Proven to Reduce Video Bandwidth, Storage and Power Consumption up to 50% with Quality Across Any Network or Hardware Platform.

• VAST (Video Adaptive Systems Technology) Platform Delivers High-Impact Results in Ultra-Low-Bandwidth Environments Where Traditional Systems Fail.

• Follow-On Order from U.S. Army Program Executive Office Soldier (PEO Soldier) for Proprietary VAST™ Video Compression Software After Initial Order in July.

• Long-Term Opportunity with US Army Could Scale Significantly, Potentially to Equip up to 10,000 Units.

• Selected for Grant-Funded Initiative to Advance Underground Mining Innovation with CRISP Enabled Remote Loader Technology.

• Initial Order from Asia-Pacific partner TEKSEA Technology Joint Stock Company to supply Vietnamese Maritime Security and Defense Services.

RMX Industries Inc. (Symbol: RMXI) is a technology company specializing in advanced data compression and video optimization. On August 1st the company officially completed its official name change from Reticulate Micro to RMX Industries, Inc., reflecting management’s expanded vision and strategic growth objectives. As part of the transition, RMXI has launched an updated website at http://www.rmx.io.

Leveraging proprietary, field-validated technology that has demonstrated exceptional performance in the most demanding environments, RMXI is transforming the way organizations capture, transmit, store, and share visual data. Originally developed for mission-critical military applications, the RMXI platform reduces video bandwidth, storage needs, and power consumption by up to 50%—all without compromising quality, functional across any network or hardware infrastructure. As data becomes a foundational asset across Defense, AI, Cloud, and Enterprise Ecosystems, RMXI is uniquely positioned to lead the next generation of intelligent, efficient data compression solutions in a rapidly digitizing world.

The Company’s 2024 was defined by rapid technological advancements and rigorous market validation of its flagship VAST platform. Originally developed for government and defense applications, RMXI VAST delivered high-impact results in ultra-low-bandwidth environments, enabling real-time video where traditional solutions fail. Multiple military exercises and test events (over 20 in 2024) have proven RMXI VAST’s ability to stream video on any communication band, including narrow-band SATCOM, L-Band and even legacy HF networks where streaming video was thought to be unviable.

Building on its success in tactical video solutions for defense applications, RMXI is expanding its enterprise-level offerings for government and commercial customers. RMXI plans to release significant platform enhancements in early 2025, including advanced dynamic bandwidth management and adaptive encoding capabilities. Additionally, through its commercial joint venture launching in Q1 2025, RMXI is positioned to bring its revolutionary technology to global commercial markets.

The RMXI 2025 strategy focuses on a platform-first roadmap designed to drive innovation, optimize performance, and scale our compression technologies across critical data environments.

Government Sector Partnership & OEM Integration

Strategic Partner Program: RMXI is launching a comprehensive integration program enabling partners and system integrators to embed VAST technology directly into their product lines and existing government contract vehicles.

Major Exercises & Evaluations: VAST has already been validated within U.S. Special Operations, multiple U.S. Army and Naval initiatives, and a range of international defense programs. This year’s schedule includes high-profile exercises with U.S. SOCOM, Army, and Navy, as well as several invitations specifically created for VAST testing and evaluation.

Commercial Scale via Joint Venture (RMX and CRISP)

Global Managed Services: RMXI and K2 Endeavor DMCC formed RMX as a joint venture to commercialize and scale VAST through a newly developed solution, CRISP (Compressed Rate Intelligent Streaming Protocol). Purpose built for commercial and enterprise sectors from telecommunications to AI, CRISP delivers next-generation data compression to meet the demands of high-performance digital infrastructure.

Recurring Revenue Model: RMX’s global managed service structure is designed to offer predictable, long-term revenue while solving critical video-delivery challenges for enterprise customers.

Expanded Product Suite

VAST Video Encoder: The core software-based video encoder product will see the addition of key features including audio, KLV metadata support, video tele-conferencing, and region of interest encoding.

VAST Vue: Cross-platform (Windows, Linux, Mac OS, Android, iOS) video player for seamless end-to-end experiences, including support for tactical metadata.

VAST SDK: Development tools and APIs for advanced integration of core VAST capabilities into partner products and solutions.

VAST Cloud: VAST-as-a-Service cloud offering for enterprise solutions, including live streaming, transcoding and VOD (video on demand) services.

Follow-On Order from U.S. Army, Confirming Momentum Toward Standardization

On August 12th RMXI announced it has received a follow-on order from the U.S. Army’s Program Executive Office Soldier (PEO Soldier) for an additional 30 units of its VAST™ software-based video compression platform.

The order follows the successful initial deployment of RMXI VAST™ within the Army’s Transformation in Contact (TIC) initiative and further signals growing recognition of RMX’s VAST™ software as a next-generation solution for high efficiency video transmission in operational environments.

RMXI VAST™ is designed for real-time, high-definition video delivery at ultra-low bitrates, functioning reliably across constrained and contested networks. Its software-based architecture allows it to run on lightweight, low-power devices without specialized hardware making it ideal for soldier-worn systems and unmanned assets.

On July 8th RMXI announced it had received its initial order from the U.S. Army’s Program Executive Office Soldier (PEO Soldier) for its proprietary VAST™ video compression software. The first order, valued at approximately $135,000, covers the deployment of 30 RMXI VAST™ units as part of the Transformation in Contact (TIC) initiative at the Joint Readiness Training Center (JRTC). TIC is designed to accelerate the integration of emerging technologies into field operations, enabling soldiers to test, adapt, and innovate in real-world conditions. RMXI is ready to support multiple TIC engagements with the Army over the next year, with the objective of providing VAST’s™ potential for enhancing situational awareness for dismounted infantry.

RMXI believes the long-term opportunity could scale significantly, with the potential to ultimately equip up to 10,000 units across the Army’s operational footprint.

RMXI Selected to Participate in Grant-Funded Initiative to Advance Underground Mining Innovation with CRISP Enabled Remote Loader Technology

On June 24th RMXI announced its participation in grant funding to conduct a groundbreaking proof of concept (PoC) focused on advancing semi-autonomous mining operations.

The initiative, branded RMX Mining, will leverage the RMXI proprietary CRISP platform to enhance tele-remote video capabilities in underground environments. As part of the project, RMXI is conducting field trials to test the use of ISM (Industrial, Scientific, and Medical) band radio frequencies for video transmission in support of Remote Loader technology.

This PoC aims to validate and quantify the benefits of the five-meter cycle, a transformative mining method that could redefine efficiency, safety, and productivity in underground operations. By enabling real-time video streaming in challenging conditions, RMXI CRISP will play a strategic role in expanding the scope and reliability of remote-controlled machinery.

The RMX Mining platform is built upon the Company’s proven success in defense and industrial applications and represents a significant step toward digitizing the future of mining.

RMXI to Deliver VAST’s Video Compression Technology to Strategic U.S. Partner

On June 4th RMXI announced it received an initial order from its Asia-Pacific partner TEKSEA Technology Joint Stock Company for VASTTM to supply a critical operational need of the Vietnamese maritime security and defense services.

TEKSEA is engaged with the Vietnamese government to design and deploy a satellite-based camera surveillance system, which includes equipping vessels with video encoding and compression systems to enable real-time transmission of surveillance footage from vessels to a command center via satellite connectivity. The ability to stream real-time video and images from cameras and sensors installed onboard ships to command centers on shore is critical to improving situational awareness and responding quickly to threats at sea.

For more information on $RMXI visit www.rmx.io

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: RMX Industries, Inc. (OTCQB: RMXI)
Contact Person: RMX Media Relations
Email: Send Email
Phone: 866-70 MICRO
Address:4220 Duncan Ave, Suite 201
City: St. Louis
State: Missouri
Country: United States
Website: www.rmx.io

Urothelial Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Urothelial Carcinoma Pipeline Insights 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the treatment Landscape. Click here to read more @ Urothelial Carcinoma Pipeline Outlook

Key Takeaways from the Urothelial Carcinoma Pipeline Report

In August 2025, Astellas Pharma Global Development, Inc. announced a study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer.
In August 2025, Merck Sharp & Dohme LLC conducted a substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
In August 2025, Seagen organized a study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease.
In August 2025, AbbVie conducted a study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio.
DelveInsight’s Urothelial Carcinoma Pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies.
The leading Urothelial Carcinoma Companies such as MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others
Promising Urothelial Carcinoma Pipeline Therapies such as Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others.

Discover groundbreaking developments in Urothelial Carcinoma therapies! Gain in-depth knowledge of key Urothelial Carcinoma clinical trials, emerging drugs, and market opportunities @ Urothelial Carcinoma Clinical Trials Assessment

Urothelial Carcinoma Emerging Drugs Profile

Pemazyre (pemigatinib): Incyte

Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

Cetrelimab: Janssen Research and Development

Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple myeloma as a combination treatment. Cetrelimab is also being evaluated in multiple combination regimens across the Janssen oncology portfolio.

Stay informed about the Urothelial Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Urothelial Carcinoma Unmet Needs

Urothelial Carcinoma Companies

MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others.

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intranasal
Intrathecal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Transdermal

Urothelial Carcinoma Products have been categorized under various Molecule types such as

Antisense oligonucleotide
Gene therapy
Hormones
Neuropeptides
Oligonucleotides
Small Molecule
Triglyceride

Transform your understanding of the Urothelial Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Urothelial Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of Urothelial Carcinoma Pipeline Report

Coverage- Global
Urothelial Carcinoma Companies- MedPacto, AstraZeneca, Helsinn/QED Therapeutics, Inovio Pharmaceuticals, Abbisko Therapeutics, Bayer, 4D pharma plc, RemeGen, Infinity Pharmaceuticals, Kyowa Kirin Inc., Ikena Oncology, Vyriad, Seagen, RemeGen, Pfizer, Incyte Corporation, Prestige BioPharma, TARIS Biomedical, Janssen Research and Development, and others.
Urothelial Carcinoma Pipeline Therapies- Avelumab, Lenvatinib, disitamab vedotin, pembrolizumab, Rogaratinib (BAY1163877), Atezolizumab, retifanlimab, epacadostat, and others
Urothelial Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Urothelial Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Urothelial Carcinoma Pipeline Analysis Today! @ Urothelial Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Urothelial Carcinoma Executive Summary

3. Urothelial Carcinoma: Overview

4. Urothelial Carcinoma Pipeline Therapeutics

5. Urothelial Carcinoma Therapeutic Assessment

6. Urothelial Carcinoma- DelveInsight’s Analytical Perspective

7. Mid Stage Products (Phase III)

8. Cetrelimab: Janssen Research and Development

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. Vactosertib: MedPacto

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I/II)

14. Drug name: Company name

15. Drug profiles in the detailed report…..

16. Early Stage Products (Phase I)

17. MV NIS: Vyriad

18. Drug profiles in the detailed report…..

19. Preclinical Stage Products

20. Drug name: Company name

21. Drug profiles in the detailed report…..

22. Inactive Products

23. Urothelial Carcinoma Key Companies

24. Urothelial Carcinoma Key Products

25. Urothelial Carcinoma- Unmet Needs

26. Urothelial Carcinoma- Market Drivers and Barriers

27. Urothelial Carcinoma- Future Perspectives and Conclusion

28. Urothelial Carcinoma Analyst Views

29. Urothelial Carcinoma Key Companies

30. Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Urothelial Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape

Eosinophilic Esophagitis Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Eosinophilic Esophagitis Pipeline Insights 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Eosinophilic Esophagitis pipeline landscape. It covers the Eosinophilic Esophagitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eosinophilic Esophagitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Eosinophilic Esophagitis Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Eosinophilic Esophagitis Pipeline Outlook Report

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

In August 2025, NexEos Diagnostics Inc. announced phase 2 study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
In August 2025, Eupraxia Pharmaceuticals Inc. conducted a Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE). Endoscopic and histologic assessments will also be evaluated to understand the local effects of EP-104GI on eosinophilic EoE disease activity.
In August 2025, Uniquity One (UNI) organized a Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
DelveInsight’s Eosinophilic Esophagitis pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Eosinophilic Esophagitis treatment.
The leading Eosinophilic Esophagitis Companies such as Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.
Promising Eosinophilic Esophagitis Therapies such as Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide, and others.

Discover how the Eosinophilic Esophagitis treatment paradigm is evolving. Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Eosinophilic Esophagitis Clinical Trials and Studies

Eosinophilic Esophagitis Emerging Drugs Profile

APT-1011: Ellodi Pharmaceuticals

APT-1011 is a novel, proprietary, once daily, investigational oral disintegrating tablet designed to deliver fluticasone propionate to the esophageal mucosa while minimizing residence time in the oral cavity. In earlier clinical trials, APT-1011 reduced esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. It is currently in clinical development, following successful completion of FLUTE I and FLUTE II. It has been granted orphan drug status by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Currently the product is in Phase III stage of development for the treatment of Eosinophilic Esophagitis.

IRL201104: Revolo Biotherapeutics

IRL201104, is uniquely safe and efficacious demonstrating immunoregulatory activity in a number of preclinical models. It has successfully completed Phase I clinical development and has the potential to be the first Immune Resetting Asthma Drug (IMRAD). 1104 is a novel linear peptide, derived from a natural immune-regulatory protein, Mycobacterium tuberculosis Chaperonin 60.1, involved in resetting the immune system. It may provide remission for many allergic diseases. 1104 engages a novel target on macrophages and is a first-in-class modulator of the macrophage response. This response engages not only the effector arm of the immune system, but the regulatory arm as well. Currently the product is in Phase II stage of development for the treatment of patients with eosinophilic esophagitis (EoE) and other Th2 allergic diseases.

AQ280: Aqilion

AQ280 is an oral, small-molecule, super selective JAK1 inhibitor. JAK1 is an enzyme, a kinase that accelerates inflammatory processes, which, among other things effects allergy and fibrosis. By inhibiting its mechanism, it is possible to reduce symptoms and disease development in chronic inflammatory diseases. Within the Regulus program, Aqilion is developing AQ280, which is a super selective JAK1 inhibitor, as a treatment of the chronic disease eosinophilic esophagitis. Data describing the pharmacokinetic profile, safety and tolerability of the drug candidate was evaluated between every dose escalation. Now, data has been collected for all dose groups and the database has been locked for statistical analysis. Currently the product is in Phase I stage of development for the treatment of patients with eosinophilic esophagitis (EoE).

The Eosinophilic Esophagitis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Eosinophilic Esophagitis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Eosinophilic Esophagitis Treatment.
Eosinophilic Esophagitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Eosinophilic Esophagitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Eosinophilic Esophagitis market.

Get a detailed analysis of the latest innovations in the Eosinophilic Esophagitis pipeline. Explore DelveInsight’s expert-driven report today! @ Eosinophilic Esophagitis Unmet Needs

Eosinophilic Esophagitis Companies

Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Eosinophilic Esophagitis Products have been categorized under various Molecule types such as

Peptide
Protein
Propylene glycols
Cell Therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Eosinophilic Esophagitis Therapies and key drug developments @ Eosinophilic Esophagitis Market Drivers and Barriers, and Future Perspectives

Scope of the Eosinophilic Esophagitis Pipeline Report

Coverage- Global
Eosinophilic Esophagitis Companies- Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.
Eosinophilic Esophagitis Therapies- Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide, and others.
Eosinophilic Esophagitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Eosinophilic Esophagitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Eosinophilic Esophagitis drug development? Find out in DelveInsight’s exclusive Eosinophilic Esophagitis Pipeline Report—access it now! @ Eosinophilic Esophagitis Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Eosinophilic Esophagitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
APT-1011: Ellodi Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
IRL201104: Revolo Biotherapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
AQ280: Aqilion
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Eosinophilic Esophagitis Key Companies
Eosinophilic Esophagitis Key Products
Eosinophilic Esophagitis- Unmet Needs
Eosinophilic Esophagitis- Market Drivers and Barriers
Eosinophilic Esophagitis- Future Perspectives and Conclusion
Eosinophilic Esophagitis Analyst Views
Eosinophilic Esophagitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eosinophilic Esophagitis Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

Metastatic Renal Cell Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insights 2025” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Renal Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Metastatic Renal Cell Carcinoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Metastatic Renal Cell Carcinoma Pipeline Outlook

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report

In August 2025, Ontario Clinical Oncology Group (OCOG) conducted a phase II clinical trial evaluating SBRT as upfront cytoreductive therapy to the primary renal mass along with combination I/N therapy in patients with intermediate/poor risk mRCC who are not candidates for cytoreductive nephrectomy. Eligible and consenting, newly diagnosed and histologically confirmed intermediate/poor risk mRCC patients based on IMDC criteria with primary disease in-situ will be randomized in a 2:1 fashion to either induction I/N followed by SBRT prior to the second cycle (experimental arm) versus I/N alone (standard arm). Patients will be stratified based on IMDC criteria (intermediate 1-2 versus poor 3-6).
DelveInsight’s Metastatic Renal Cell Carcinoma Pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
The leading Metastatic Renal Cell Carcinoma Companies such as AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
Promising Metastatic Renal Cell Carcinoma Therapies such as Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.

Stay ahead with the most recent pipeline outlook for Metastatic Renal Cell Carcinoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Metastatic Renal Cell Carcinoma Treatment

Metastatic Renal Cell Carcinoma Emerging Drugs Profile

Olaparib: AstraZeneca

Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

Atezolizumab: Genentech

Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

TP-1454: Sumitomo Dainippon Pharma

TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.

The Metastatic Renal Cell Carcinoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Renal Cell Carcinoma Treatment.
Metastatic Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Metastatic Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Renal Cell Carcinoma market.

Explore groundbreaking therapies and clinical trials in the Metastatic Renal Cell Carcinoma Pipeline. Access DelveInsight’s detailed report now! @ New Metastatic Renal Cell Carcinoma Drugs

Metastatic Renal Cell Carcinoma Companies

AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Unveil the future of Metastatic Renal Cell Carcinoma treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers

Scope of the Metastatic Renal Cell Carcinoma Pipeline Report

Coverage- Global
Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd and others.
Metastatic Renal Cell Carcinoma Therapies- Cabozantinib, Pembrolizumab, Epacadostat, Sunitinib, BGB-A445, Tislelizumab, and others.
Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Metastatic Renal Cell Carcinoma therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Metastatic Renal Cell Carcinoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Metastatic Renal Cell Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Atezolizumab: Genentech
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Olaparib: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TP-1454: Sumitomo Dainippon Pharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Metastatic Renal Cell Carcinoma Key Companies
Metastatic Renal Cell Carcinoma Key Products
Metastatic Renal Cell Carcinoma- Unmet Needs
Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
Metastatic Renal Cell Carcinoma Analyst Views
Metastatic Renal Cell Carcinoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Renal Cell Carcinoma Pipeline Outlook Report 2025: Key 40+ Companies and Breakthrough Therapies Shaping the Future Landscape

Biliary Tract Cancer Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Biliary Tract Cancers Pipeline Insights 2025” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Biliary Tract Cancers pipeline landscape. It covers the Biliary Tract Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Biliary Tract Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Biliary Tract Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Biliary Tract Cancer Pipeline Outlook Report

Key Takeaways from the Biliary Tract Cancer Pipeline Report

In August 2025, AstraZeneca announced a study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are ≥ 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy. Participants with WHO/ECOG PS 2 will be capped at 20% of the overall treated participant population.
In August 2025, Eli Lilly and Company conducted a study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
In August 2025, Boehringer Ingelheim announced a study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly.
In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).
In August 2025, Incyte Corporation announced a Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.
DelveInsight’s Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Biliary Tract Cancer treatment.
The leading Biliary Tract Cancer Companies such as Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT Bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited and others.
Promising Biliary Tract Cancer Therapies such as PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.

Discover how the Biliary Tract Cancer Treatment paradigm is evolving. Access DelveInsight’s in-depth Biliary Tract Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Biliary Tract Cancer Clinical Trials and Studies

Biliary tract cancer: Emerging Drugs Profile

MRG 002: Miracogen

MRG 002, is an antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. An open-label, single-arm, multi-center, phase II Clinical Study of MRG002 are conducted by Miracogen for the treatment of patients with HER2-positive unresectable, locally advanced or metastatic biliary tract cancer. MRG002 is administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).

Disitamab vedotin: Yantai Rongchang Pharmaceutical

Disitamab Vedotin is an antibody-drug conjugate with a drug structure consisting of three parts Anti-human epidermal growth factor receptor 2 extracellular domain (HER2 ECD) antibody; Linker (MC-Val-Cit-PAB, Linker); and Cytotoxic Monomethyl Auristatin E (Monomethyl Auristatin E, MMAE). This product is white to light yellow loose body, after reconstitution, it is colorless to light yellow clear liquid.

Envafolimab: Alphamab Oncology

Envafolimab is a PD-L1 single-domain antibody Fc fusion protein independently developed by Alphamab. Based on the unique design, Envafolimab has advantages in safety, convenience and compliance, and can be used for patients who are not suitable for intravenous infusion with a lower medical cost. On March 30, 2020, Alphamab, 3D Medicines and Simcere reached a three-way strategic collaboration. Alphamab, as the original research party, is responsible for production and quality, 3D Medicines is responsible for global clinical development in the field of oncology, registration and commercialization abroad, and Simcere is responsible for the exclusive commercial promotion of the product in mainland China. At present, Envafolimab is being evaluated in clinical trials for multiple cancer indications in China, the United States and Japan, and the research for multiple indications have entered the registration/clinical Phase III. Envafolimab has been awarded orphan drug designation (ODD) by FDA in the United States for the treatment of advanced biliary tract cancer.

DKN-01: Leap Therapeutics

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The U.S. Food and Drug Administration has granted DKN-01 Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancer and Fast Track Designation in combination with tislelizumab for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express high DKK1 protein, following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, human epidermal receptor growth factor (HER2)/neu-targeted therapy. Currently the drug is in Phase II of development.

Get a detailed analysis of the latest innovations in the Biliary Tract Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Biliary Tract Cancer Unmet Needs

Biliary Tract Cancer Companies

Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT Bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited and others.

Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Biliary Tract Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming Biliary Tract Cancer Therapies and key Biliary Tract Cancer Developments @ Biliary Tract Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Biliary Tract Cancer Pipeline Report

Coverage- Global
Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT Bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee’s Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee’s Pharmaceutical Limited and others.
Biliary Tract Cancer Therapies- PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.
Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Biliary Tract Cancer drug development? Find out in DelveInsight’s exclusive Biliary Tract Cancer Pipeline Report—access it now! @ Biliary Tract Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Biliary Tract Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Biliary Tract Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Envafolimab: Alphamab Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
SMT-NK: SMT bio Co., Ltd.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
HA121-28: CSPC ZhongQi Pharmaceutical Technology
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ZKAB001: Lee’s Pharmaceutical Limited
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Biliary Tract Cancer Key Companies
Biliary Tract Cancer Key Products
Biliary Tract Cancer- Unmet Needs
Biliary Tract Cancer- Market Drivers and Barriers
Biliary Tract Cancer- Future Perspectives and Conclusion
Biliary Tract Cancer Analyst Views
Biliary Tract Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biliary Tract Cancer Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape

Prostate Cancer Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Prostate Cancer Pipeline Insight 2025” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prostate Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Prostate Cancer Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Prostate Cancer Pipeline Outlook Report

Key Takeaways from the Prostate Cancer Pipeline Report

In August 2025, Bayer conducted a study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).
DelveInsight’s Prostate Cancer pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Prostate Cancer treatment.
The leading Prostate Cancer Companies such as Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, and Cellbion Co., Ltd., and others.
Promising Prostate Cancer Pipeline such as Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

Stay ahead with the most recent pipeline outlook for Prostate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prostate Cancer Treatment Drugs

Prostate Cancer Emerging Drugs

Niraparib: Janssen Research & Development

Niraparib is an orally administered selective poly ADP-ribose polymerase (PARP) inhibitor. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO for exclusive rights to niraparib in prostate cancer. In the US, niraparib is indicated for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK. The drug is currently being evaluated in Phase III clinical trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mCSPC).

ZEN 3694: Zenith Epigenetics

ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. The drug is currently being evaluated in the Phase II stage of its development for the treatment of Prostate cancer.

Ladiratuzumab vedotin: Seagen

Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics’ proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently, the drug is in the Phase II stage of its development for the treatment of Prostate Cancer.

FOR46: Fortis Therapeutics

FOR46 is a fully human antibody conjugated to a potent payload, depending on the indication. Fortis Therapeutics is developing FOR46, a novel antibody-drug conjugate (ADC) against CD46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Company is also evaluating additional indications for FOR46. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

REGN5678: Regeneron Pharmaceuticals

REGN5678 is designed to bind to CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA on tumor cells. By binding to the costimulatory T-cell-specific surface glycoprotein and tumor-associated antigen, the drug candidate could activate CTLs and direct them to attack cancer cells. Regeneron identified the targeting of CD28 on previously activated T cells as a way to reduce toxicity compared to CD3 bispecifics. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

The Prostate Cancer Pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.
Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.

Explore groundbreaking therapies and clinical trials in the Prostate Cancer Pipeline. Access DelveInsight’s detailed report now! @ New Prostate Cancer Drugs

Prostate Cancer Companies

Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.

Prostate Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of Prostate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Prostate Cancer Market Drivers and Barriers

Scope of the Prostate Cancer Pipeline Report

Coverage- Global
Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
Prostate Cancer Pipeline- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Prostate Cancer drug development? Find out in DelveInsight’s exclusive Prostate Cancer Pipeline Report—access it now! @ Prostate Cancer Emerging Drugs and Major Companies

Table of contents

Introduction
Executive Summary
Prostate Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Prostate Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Niraparib: Janssen Research & Development
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ZEN 3694: Zenith Epigenetics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
FOR46: Fortis Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Product Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Pipeline Outlook Report 2025: Key 140+ Companies and Breakthrough Therapies Shaping the Future Landscape

Generalized Myasthenia Gravis Market to Surge Through 2034 as FcRn Blockers and Complement Inhibitors Gain Momentum | DelveInsight

“Generalized Myasthenia Gravis Market Insight, Epidemiology And Market Forecast – 2034”

DelveInsight projects significant gMG market growth in 7MM through 2034, driven by novel therapies from Alexion, argenx, UCB Biopharma, Horizon Therapeutics, Hoffmann-La Roche, Johnson & Johnson, Immunovant, Bristol Myers Squibb, Biogen, Pfizer, Novartis, and Sanofi. Advances include FcRn blockers, complement inhibitors, and key approvals for eculizumab, efgartigimod, rozanolixizumab, and nipocalimab.

DelveInsight’s “Generalized Myasthenia Gravis Market Insight, Epidemiology And Market Forecast – 2034” report delivers a comprehensive analysis of the GnRH Receptor Antagonist market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Key Takeaways

Market size projection: As per DelveInsight’s analysis, the total market size of Generalized Myasthenia Gravis in the 7MM is expected to surge significantly by 2034, driven by novel therapies and expanding patient access.
Patient population data: The report provides the total Generalized Myasthenia Gravis diagnosed prevalent pool, detailing gender-specific and autoantibody-defined subgroups across the United States, EU-5, and Japan.
Key companies: Leading Generalized Myasthenia Gravis companies, such as Alexion Pharmaceuticals, argenx, UCB Biopharma, Horizon Therapeutics, and Hoffmann-La Roche, anchor current and emerging treatment landscapes.
Pipeline assets: Some of the key Generalized Myasthenia Gravis therapies in the pipeline include nipocalimab, efgartigimod (VYVGART Hytrulo), and rozanolixizumab.
Unmet needs spotlight: Current challenges include optimizing long-term immunosuppression, reducing corticosteroid side effects, and improving patient access to high-cost biologics.
In January 2025, the FDA granted Priority Review to Johnson & Johnson’s nipocalimab Biologics License Application for antibody-positive gMG patients.
In March 2025, eculizumab (SOLIRIS) received FDA approval for pediatric patients aged 6 years and older with anti-AChR-positive gMG.
In April 2025, argenx launched a prefilled syringe formulation of subcutaneous efgartigimod (VYVGART Hytrulo) for self-administration.
In April 2020, the European Commission granted Orphan Drug Designation to UCB’s rozanolixizumab for gMG.
Total diagnosed cases in the 7MM are projected to rise steadily from 2024 through 2034, reflecting improved diagnosis and expanded treatment eligibility.

Discover recent advancements in the Generalized Myasthenia Gravis treatment landscape @ Generalized Myasthenia Gravis Recent Developments.

Generalized Myasthenia Gravis Market Dynamics

The current generalized myasthenia gravis market in the 7MM is estimated at USD 2,700 million in 2021, with a robust compound annual growth rate anticipated through 2034. This growth is underpinned by evolving therapeutic paradigms that transition from symptomatic cholinesterase inhibitors and corticosteroids to targeted immunomodulators and complement inhibitors. The generalized myasthenia gravis market is further propelled by increasing disease awareness, enhanced diagnostic algorithms, and the introduction of first-in-class modalities such as FcRn blockers and complement C5 inhibitors. Rising prevalence and improved detection of anti-AChR and anti-MuSK antibody subtypes further expand the addressable patient pool, reinforcing market evolution.

The generalized myasthenia gravis emerging therapies primarily focus on precise modulation of pathogenic immunoglobulins and complement pathways. FcRn antagonists, exemplified by efgartigimod and rozanolixizumab, facilitate accelerated clearance of pathogenic IgG, addressing the root immunopathology of gMG. Complement inhibition by eculizumab disrupts the terminal complement cascade implicated in neuromuscular junction damage. These mechanisms, validated in pivotal trials, establish a strong therapeutic rationale and support favorable benefit-risk profiles.

The generalized myasthenia gravis clinical development activity remains intense. Rozanolixizumab and nipocalimab advance through Phase III studies, while additional candidate molecules explore novel targets such as LRP4 and alternative Fc receptor interactions. Strategic partnerships and licensing deals have accelerated trial enrollment and regulatory filings. Industry participation is broad, with over 20 companies engaged in gMG R&D, deploying diverse strategic approaches from small-molecule immunosuppressants to next-generation biologics.

Despite advances, challenges persist. High development costs and complex manufacturing constrain pricing and access, particularly for pediatric and elderly patients. Corticosteroid augmentation remains common despite long-term toxicity concerns, underscoring the need for safer maintenance therapies. Market opportunities lie in expanding subcutaneous and self-administered formulations, telemedicine-enabled monitoring, and biomarker-driven patient stratification to optimize therapeutic outcomes.

Looking ahead, the generalized myasthenia gravis market growth drivers include regulatory incentives such as Orphan Drug Designations, streamlined approval pathways for antibody-positive subgroups, and strong physician and patient advocacy. The integration of real-world evidence to support label expansions and reimbursement negotiations will further bolster market expectations. As mechanistic insights deepen and pipeline innovations mature, the gMG market is poised for sustained expansion and improved patient outcomes through 2034.

Download the Generalized Myasthenia Gravis Market report to understand which factors are driving the therapeutic market @ Generalized Myasthenia Gravis Market Trends.

Generalized Myasthenia Gravis Epidemiology

Generalized Myasthenia Gravis epidemiology reveals a progressively increasing diagnosed prevalence from 2020 through the forecast period ending in 2034 across 7MM. The report segments epidemiology by total diagnosed cases, gender-specific distribution, and autoantibody-defined subpopulations (anti-AChR, anti-MuSK, and anti-LRP4). Acknowledging the heterogeneity of gMG, the analysis delineates the potential patient pool eligible for novel immunotherapies versus those managed with conventional immunosuppressants.

Total generalized myasthenia gravis diagnosed prevalent cases across the 7MM are mapped, illustrating rising detection rates due to enhanced diagnostic guidelines. The total eligible patient pool, comprising antibody-positive and clinically confirmed gMG, is estimated to grow in parallel with expanded screening practices and increased physician awareness. Total treated cases reflect current uptake of symptomatic treatments, short-term immunomodulators (IVIG and plasmapheresis), and emerging biologics.

Furthermore, geographic segmentation underscores the United States as the largest market contributor, followed by the United Kingdom and Germany. Japan demonstrates steady growth driven by the early adoption of complement inhibitors. The EU-5 collectively contributes a substantial diagnosed pool, with regional variations influenced by national treatment guidelines and reimbursement frameworks. Over the 2024–2034 forecast period, diagnosed prevalence and treated patient numbers are projected to increase by double-digit percentages, reflecting both epidemiological shifts and expanding therapeutic eligibility.

Discover evolving trends in the Generalized Myasthenia Gravis patient pool forecasts @ Generalized Myasthenia Gravis Epidemiology Analysis.

Key Generalized Myasthenia Gravis Companies and Treatment Market

The clinical and regulatory landscape is characterized by a mix of established immunosuppressants and innovative biologics. Current generalized myasthenia gravis treatment options include acetylcholinesterase inhibitors (pyridostigmine), corticosteroids, and long-term immunosuppressants such as azathioprine and mycophenolate mofetil. Rapid-acting modalities, intravenous immunoglobulin and plasma exchange, address acute exacerbations, while thymectomy remains an anatomical intervention for select patients.

According to DelveInsight’s report, the generalized myasthenia gravis clinical pipeline activity is robust. UCB Biopharma’s rozanolixizumab is in late-stage development as a subcutaneously administered FcRn blocker. Johnson & Johnson’s nipocalimab has achieved FDA Priority Review for antibody-positive gMG, encompassing anti-AChR, anti-MuSK, and anti-LRP4 subtypes. argenx’s efgartigimod (VYVGART Hytrulo) recently received a prefilled syringe formulation for self-administration, enhancing patient convenience and adherence. These agents, alongside investigational molecules targeting alternative immunopathways, underscore the depth of ongoing studies.

Key generalized myasthenia gravis companies include Alexion Pharmaceuticals (eculizumab), argenx (efgartigimod), UCB Biopharma (rozanolixizumab), Horizon Therapeutics, Hoffmann-La Roche, Janssen Research & Development, Immunovant Sciences, Bristol Myers Squibb, Biogen Inc., Pfizer Inc., Novartis AG, Sanofi S.A., and Roche Holding AG. Each company pursues distinct positioning, from complement inhibition to FcRn blockade, aligning with current treatment paradigms that emphasize targeted immunomodulation.

The generalized myasthenia gravis drug profiles highlight mechanisms of action, FcRn receptor antagonism for efgartigimod and rozanolixizumab, complement C5 blockade for eculizumab, and detail development status, including pivotal Phase III trial results demonstrating rapid and durable symptom improvement. Recent regulatory designations, such as FDA pediatric approval for eculizumab and European Orphan Drug status for rozanolixizumab, reflect critical development milestones. Partnerships and licensing agreements, including argenx’s collaboration with Halozyme for subcutaneous delivery technology, illustrate strategic collaborations driving commercialization readiness.

Commercial arrangements focus on patient support programs, copay assistance, and reimbursement strategies to mitigate high out-of-pocket costs associated with biologic therapies. As companies advance late-stage assets toward approval, market positioning will hinge on differentiating safety profiles, administration routes, and real-world effectiveness to capture share in the expanding gMG treatment landscape.

Discover which companies are innovating in the Generalized Myasthenia Gravis treatment landscape @ Generalized Myasthenia Gravis Competitive Landscape.

Conclusion

The DelveInsight report underscores a transformative era in Generalized Myasthenia Gravis, marked by expanding epidemiology, novel targeted therapies, and strategic industry collaboration. Continued innovation and strategic market access initiatives will be pivotal in meeting unmet medical needs and driving sustained growth through 2034.

Table of Contents

1. Key Insights

2. Executive Summary of Generalized Myasthenia Gravis

3. Competitive Intelligence Analysis for Generalized Myasthenia Gravis

4. Generalized Myasthenia Gravis Market Overview at a Glance

5. Generalized Myasthenia Gravis: Disease Background and Overview

6. Generalized Myasthenia Gravis Patient Journey

7. Generalized Myasthenia Gravis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Generalized Myasthenia Gravis Unmet Needs

10. Key Endpoints of Generalized Myasthenia Gravis Treatment

11. Generalized Myasthenia Gravis Marketed Products

12. Generalized Myasthenia Gravis Emerging Therapies

13. Generalized Myasthenia Gravis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Generalized Myasthenia Gravis

17. KOL Views

18. Generalized Myasthenia Gravis Market Drivers

19. Generalized Myasthenia Gravis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Generalized Myasthenia Gravis Market to Surge Through 2034 as FcRn Blockers and Complement Inhibitors Gain Momentum | DelveInsight